# Insulet Corp: financial statements, quarterly

PODD · Nasdaq · CIK 1145197 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/podd.md) · [Financials](/companies/podd/financials.md) · [Filings](/companies/podd/filings.md) · [Insiders](/companies/podd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/podd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [433](/filings/0001145197-24-000045.md) | [510 d](/filings/0001145197-26-000028.md) | [442](/filings/0001145197-25-000022.md) | [489](/filings/0001145197-25-000038.md) | [544](/filings/0001145197-25-000069.md) | [598 d](/filings/0001145197-26-000028.md) | [569](/filings/0001145197-26-000102.md) | [649](/filings/0001145197-26-000169.md) | [706](/filings/0001145197-25-000069.md) | [784 d](/filings/0001145197-26-000028.md) | [762](/filings/0001145197-26-000102.md) | [802](/filings/0001145197-26-000169.md) |
| Cost of revenue | $m | [139](/filings/0001145197-24-000045.md) | [149 d](/filings/0001145197-26-000028.md) | [135](/filings/0001145197-25-000022.md) | [158](/filings/0001145197-25-000038.md) | [167](/filings/0001145197-25-000069.md) | [167 d](/filings/0001145197-26-000028.md) | [160](/filings/0001145197-26-000102.md) | [197](/filings/0001145197-26-000169.md) | [196](/filings/0001145197-25-000069.md) | [215 d](/filings/0001145197-26-000028.md) | [233](/filings/0001145197-26-000102.md) | [239](/filings/0001145197-26-000169.md) |
| Gross profit | $m | [293](/filings/0001145197-24-000045.md) | [361 d](/filings/0001145197-26-000028.md) | [307](/filings/0001145197-25-000022.md) | [331](/filings/0001145197-25-000038.md) | [377](/filings/0001145197-25-000069.md) | [431 d](/filings/0001145197-26-000028.md) | [409](/filings/0001145197-26-000102.md) | [452](/filings/0001145197-26-000169.md) | [510](/filings/0001145197-25-000069.md) | [569 d](/filings/0001145197-26-000028.md) | [529](/filings/0001145197-26-000102.md) | [563](/filings/0001145197-26-000169.md) |
| Research and development | $m | [57.8](/filings/0001145197-24-000045.md) | [42.0 d](/filings/0001145197-26-000028.md) | [50.2](/filings/0001145197-25-000022.md) | [53.9](/filings/0001145197-25-000038.md) | [54.9](/filings/0001145197-25-000069.md) | [60.6 d](/filings/0001145197-26-000028.md) | [59.6](/filings/0001145197-26-000102.md) | [73.4](/filings/0001145197-26-000169.md) | [77.2](/filings/0001145197-25-000069.md) | [90.9 d](/filings/0001145197-26-000028.md) | [89.7](/filings/0001145197-26-000102.md) | [88.1](/filings/0001145197-26-000169.md) |
| Selling, general and administrative | $m | [181](/filings/0001145197-24-000045.md) | [213 d](/filings/0001145197-26-000028.md) | [200](/filings/0001145197-25-000022.md) | [223](/filings/0001145197-25-000038.md) | [234](/filings/0001145197-25-000069.md) | [261 d](/filings/0001145197-26-000028.md) | [261](/filings/0001145197-26-000102.md) | [258](/filings/0001145197-26-000169.md) | [315](/filings/0001145197-25-000069.md) | [331 d](/filings/0001145197-26-000028.md) | [317](/filings/0001145197-26-000102.md) | [345](/filings/0001145197-26-000169.md) |
| Operating income | $m | [54.8](/filings/0001145197-24-000045.md) | [107 d](/filings/0001145197-26-000028.md) | [56.9](/filings/0001145197-25-000022.md) | [54.5](/filings/0001145197-25-000038.md) | [88.1](/filings/0001145197-25-000069.md) | [109 d](/filings/0001145197-26-000028.md) | [88.8](/filings/0001145197-26-000102.md) | [121](/filings/0001145197-26-000169.md) | [118](/filings/0001145197-25-000069.md) | [146 d](/filings/0001145197-26-000028.md) | [122](/filings/0001145197-26-000102.md) | [130](/filings/0001145197-26-000169.md) |
| Interest expense | $m | [10.4](/filings/0001145197-23-000076.md) | [6.7 d](/filings/0001145197-24-000011.md) | [10.7](/filings/0001145197-24-000022.md) | [11.0](/filings/0001145197-25-000038.md) | [12.4](/filings/0001145197-25-000069.md) | [8.6 d](/filings/0001145197-26-000028.md) | [9.2](/filings/0001145197-26-000102.md) | [19.6](/filings/0001145197-26-000169.md) | [15.6](/filings/0001145197-25-000069.md) | [14.9 d](/filings/0001145197-26-000028.md) | [14.7](/filings/0001145197-26-000102.md) | [13.5](/filings/0001145197-26-000169.md) |
| Income tax | $m | [1.8](/filings/0001145197-24-000045.md) | [4.5 d](/filings/0001145197-26-000028.md) | [3.4](/filings/0001145197-25-000022.md) | [(138)](/filings/0001145197-25-000038.md) | [5.4](/filings/0001145197-25-000069.md) | [10.7 d](/filings/0001145197-26-000028.md) | [12.7](/filings/0001145197-26-000102.md) | [5.9](/filings/0001145197-26-000169.md) | [35.2](/filings/0001145197-25-000069.md) | [38.5 d](/filings/0001145197-26-000028.md) | [21.9](/filings/0001145197-26-000102.md) | [23.7](/filings/0001145197-26-000169.md) |
| Net income | $m | [51.9](/filings/0001145197-24-000045.md) | [103 d](/filings/0001145197-26-000028.md) | [51.5](/filings/0001145197-25-000022.md) | [189](/filings/0001145197-25-000038.md) | [77.5](/filings/0001145197-25-000069.md) | [101 d](/filings/0001145197-26-000028.md) | [35.4](/filings/0001145197-26-000102.md) | [22.5](/filings/0001145197-26-000169.md) | [87.6](/filings/0001145197-25-000069.md) | [102 d](/filings/0001145197-26-000028.md) | [91.1](/filings/0001145197-26-000102.md) | [95.0](/filings/0001145197-26-000169.md) |
| Diluted EPS | $ per share | [0.74](/filings/0001145197-24-000045.md) | not reported | [0.73](/filings/0001145197-25-000022.md) | [2.59](/filings/0001145197-25-000038.md) | [1.08](/filings/0001145197-25-000069.md) | not reported | [0.50](/filings/0001145197-26-000102.md) | [0.32](/filings/0001145197-26-000169.md) | [1.24](/filings/0001145197-25-000069.md) | not reported | [1.30](/filings/0001145197-26-000102.md) | [1.37](/filings/0001145197-26-000169.md) |
| Basic EPS | $ per share | [0.74](/filings/0001145197-24-000045.md) | not reported | [0.74](/filings/0001145197-25-000022.md) | [2.69](/filings/0001145197-25-000038.md) | [1.11](/filings/0001145197-25-000069.md) | not reported | [0.50](/filings/0001145197-26-000102.md) | [0.32](/filings/0001145197-26-000169.md) | [1.24](/filings/0001145197-25-000069.md) | not reported | [1.30](/filings/0001145197-26-000102.md) | [1.37](/filings/0001145197-26-000169.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [1,471](/filings/0001145197-23-000076.md) | [1,583](/filings/0001145197-25-000007.md) | [1,618](/filings/0001145197-24-000022.md) | [1,749](/filings/0001145197-24-000039.md) | [1,861](/filings/0001145197-24-000045.md) | [1,891](/filings/0001145197-26-000028.md) | [2,328](/filings/0001145197-25-000022.md) | [2,280](/filings/0001145197-25-000038.md) | [1,859](/filings/0001145197-25-000069.md) | [1,914](/filings/0001145197-26-000169.md) | [1,710](/filings/0001145197-26-000102.md) | [1,849](/filings/0001145197-26-000169.md) |
| Total assets | $m | [2,468](/filings/0001145197-23-000076.md) | [2,588](/filings/0001145197-25-000007.md) | [2,624](/filings/0001145197-24-000022.md) | [2,882](/filings/0001145197-24-000039.md) | [3,025](/filings/0001145197-24-000045.md) | [3,088](/filings/0001145197-26-000028.md) | [3,517](/filings/0001145197-25-000022.md) | [3,469](/filings/0001145197-25-000038.md) | [3,029](/filings/0001145197-25-000069.md) | [3,190](/filings/0001145197-26-000169.md) | [2,987](/filings/0001145197-26-000102.md) | [3,165](/filings/0001145197-26-000169.md) |
| Current liabilities | $m | [451](/filings/0001145197-23-000076.md) | [451](/filings/0001145197-25-000007.md) | [432](/filings/0001145197-24-000022.md) | [486](/filings/0001145197-24-000039.md) | [506](/filings/0001145197-24-000045.md) | [528](/filings/0001145197-26-000028.md) | [520](/filings/0001145197-25-000022.md) | [1,010](/filings/0001145197-25-000038.md) | [648](/filings/0001145197-25-000069.md) | [680](/filings/0001145197-26-000169.md) | [688](/filings/0001145197-26-000102.md) | [744](/filings/0001145197-26-000169.md) |
| Total liabilities | $m | [1,860](/filings/0001145197-23-000076.md) | [1,856](/filings/0001145197-25-000007.md) | [1,833](/filings/0001145197-24-000022.md) | [1,883](/filings/0001145197-24-000039.md) | [1,907](/filings/0001145197-24-000045.md) | [1,876](/filings/0001145197-26-000028.md) | [2,187](/filings/0001145197-25-000022.md) | [2,006](/filings/0001145197-25-000038.md) | [1,645](/filings/0001145197-25-000069.md) | [1,675](/filings/0001145197-26-000169.md) | [1,685](/filings/0001145197-26-000102.md) | [1,743](/filings/0001145197-26-000169.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [49.8](/filings/0001145197-23-000076.md) | [49.4](/filings/0001145197-25-000007.md) | [38.9](/filings/0001145197-24-000022.md) | [37.9](/filings/0001145197-24-000039.md) | [42.0](/filings/0001145197-24-000045.md) | [83.8](/filings/0001145197-26-000028.md) | [83.1](/filings/0001145197-25-000022.md) | [461](/filings/0001145197-25-000038.md) | [79.9](/filings/0001145197-25-000069.md) | [18.4](/filings/0001145197-26-000169.md) | [18.6](/filings/0001145197-26-000102.md) | [18.9](/filings/0001145197-26-000169.md) |
| Shareholders' equity | $m | [608](/filings/0001145197-24-000045.md) | [733](/filings/0001145197-26-000028.md) | [791](/filings/0001145197-25-000038.md) | [998](/filings/0001145197-25-000069.md) | [1,118](/filings/0001145197-25-000069.md) | [1,212](/filings/0001145197-26-000169.md) | [1,331](/filings/0001145197-26-000169.md) | [1,463](/filings/0001145197-26-000169.md) | [1,384](/filings/0001145197-25-000069.md) | [1,515](/filings/0001145197-26-000169.md) | [1,303](/filings/0001145197-26-000169.md) | [1,422](/filings/0001145197-26-000169.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [56.0 d](/filings/0001145197-24-000045.md) | [45.2 d](/filings/0001145197-26-000028.md) | [87.6](/filings/0001145197-25-000022.md) | [86.8 d](/filings/0001145197-25-000038.md) | [108 d](/filings/0001145197-25-000069.md) | [148 d](/filings/0001145197-26-000028.md) | [63.8](/filings/0001145197-26-000102.md) | [197 d](/filings/0001145197-26-000169.md) | [126 d](/filings/0001145197-25-000069.md) | [183 d](/filings/0001145197-26-000028.md) | [114](/filings/0001145197-26-000102.md) | [88.4 d](/filings/0001145197-26-000169.md) |
| Capital expenditure | $m | [20.1 d](/filings/0001145197-24-000045.md) | [29.3 d](/filings/0001145197-26-000028.md) | [22.1](/filings/0001145197-25-000022.md) | [22.5 d](/filings/0001145197-25-000038.md) | [26.7 d](/filings/0001145197-25-000069.md) | [53.6 d](/filings/0001145197-26-000028.md) | [12.3](/filings/0001145197-26-000102.md) | [18.6 d](/filings/0001145197-26-000169.md) | [25.6 d](/filings/0001145197-25-000069.md) | [135 d](/filings/0001145197-26-000028.md) | [24.3](/filings/0001145197-26-000102.md) | [32.5 d](/filings/0001145197-26-000169.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001145197-25-000069.md) | [0.0 d](/filings/0001145197-26-000028.md) | [0.0](/filings/0001145197-26-000102.md) | [30.1 d](/filings/0001145197-26-000169.md) | [29.5 d](/filings/0001145197-25-000069.md) | [0.0 d](/filings/0001145197-26-000028.md) | [300](/filings/0001145197-26-000102.md) | [0.0 d](/filings/0001145197-26-000169.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [69.4](/filings/0001145197-23-000076.md) | [70.1](/filings/0001145197-24-000022.md) | [70.1](/filings/0001145197-24-000039.md) | [73.6](/filings/0001145197-24-000045.md) | [73.7](/filings/0001145197-25-000022.md) | [73.8](/filings/0001145197-25-000038.md) | [74.0](/filings/0001145197-25-000069.md) | [74.1](/filings/0001145197-26-000102.md) | [70.7](/filings/0001145197-26-000169.md) | [70.7](/filings/0001145197-25-000069.md) | [70.2](/filings/0001145197-26-000102.md) | [69.4](/filings/0001145197-26-000169.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,354,199 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001145197-26-000169.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.